

October 27, 2015

Phase 1 Clinical Trial Commences

MMJ PhytoTech Limited's (ASX:MMJ) Management and Board are pleased to announce the commencement of the Phase 1 Clinical Trials being undertaken in Israel.

A summary of the Phase 1 Clinical Trial was released to the market on July 6, 2015.

Ends

For more information please contact

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Gaelan Bloomfield
Manager, Marketing & PR
+61 431 303 567
gbloomfield@mmj.ca

Daniel Fraser
Director, Corporate Finance
Merchant Corporate Finance
dfraser@merchantcorporate.com.au

For media enquiries
Media & Capital Partners
Asher Moses, Director
+61 438 008 616

About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.



ASX RELEASE

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.